Adimmune to start clinical tests on flu vaccines in EU
ROC Central News Agency
2010/09/29 18:07:38
By Chang Liang-chih and Frances Huang
Taipei, Sept. 29 (CNA) Adimmune Corp., Taiwan's only human vaccine manufacturer, said Wednesday it will start clinical tests on its seasonal flu vaccines in the European Union in October in a bid to obtain EU certification.
"The tests will kick off in mid-October. If all goes smoothly, the company should obtain the license approval from the EU in June 2011," Adimmune Vice President Simon Kao said.
"After approval is granted, the company's seasonal flu vaccines will be allowed to go on sale in all EU member countries. We look forward to being in the huge EU market," Kao said.
In August, Adimmune's production facilities were certified by the European Medicines Agency (EMA) , the EU's pharmaceutical regulatory body. The EMA certification means that the company's production equipment meets EU requirements.
"This is part of our effort to develop sales overseas as demand for H1N1 vaccines in Taiwan is on the decline," Kao said.
The government's purchases of H1N1 vaccines from Adimmune accounted for about 80 percent of the company's total revenue in 2009. The company is the sole H1N1 vaccine provider in Taiwan.
Apart from the EU market, Kao said his company is also targeting Malaysia, the Philippines and Hong Kong as potential markets for seasonal flu vaccine sales.
Kao added that his company is planning to unveil vaccines against avian flu in July 2011 and against the enterovirus in 2015.
Meanwhile, Adimmune was listed on the GreTai Securities Market as an emerging stock on Wednesday. The company sees the move as a stepping stone to listing on Taiwan's main stock exchange, which it hopes to achieve by the fourth quarter of next year.
|
NEWSLETTER
|
| Join the GlobalSecurity.org mailing list |
|
|
|
